{{Drugbox
| IUPAC_name    = 6-[(2''S'',3''S'')-2-[(2''S'')-2-hexanamido-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]hexanamide
| image         = Dihexa.svg
| width         = 250

<!--Clinical data-->
| tradename                =
| routes_of_administration =
| legal_status =
| synonyms = N-(1-Oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide

<!--Identifiers-->
| CAS_number = 1401708-83-5
| ATC_suffix     =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9WYX65A5C2
| PubChemSubstance = 162064814
| ChemSpiderID      = 57582587
<!--Chemical data-->
| C=27 | H=44 | N=4 | O=5
| smiles = CCCCCC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCCCCCC(N)=O
| StdInChI = 1S/C27H44N4O5/c1-4-6-8-12-24(34)30-22(18-20-13-15-21(32)16-14-20)26(35)31-25(19(3)5-2)27(36)29-17-10-7-9-11-23(28)33/h13-16,19,22,25,32H,4-12,17-18H2,1-3H3,(H2,28,33)(H,29,36)(H,30,34)(H,31,35)/t19-,22-,25-/m0/s1
| StdInChIKey = XEUVNVNAVKZSPT-JTJYXVOQSA-N
}}

'''Dihexa''' (developmental code name '''PNB-0408'''), also known as '''''N''-hexanoic-Tyr-Ile-(6) aminohexanoic amide''', is an [[oligopeptide]] [[drug]] derived from [[angiotensin|angiotensin IV]] that binds with high [[affinity (pharmacology)|affinity]] to [[hepatocyte growth factor]] (HGF) and potentiates its activity at its receptor, [[c-Met]]. The compound has been found to potently improve cognitive function in [[animal model]]s of [[Alzheimer's disease]]-like [[cognitive deficit|mental impairment]].<ref>{{cite web | url=http://www.google.com/patents/US8598118 | title=Patent US 8598118 - Hepatocyte growth factor mimics as therapeutic agents | date=3 December 2013 | accessdate=11 October 2015 |author1=Joseph W. Harding |author2=John W. Wright |author3=Caroline C. Benoist |author4=Leen H. Kawas |author5=Gary A. Wayman }}</ref><ref>{{cite journal | author1=Alene T. McCoy | title=Evaluation of metabolically stabilized angiotensin IV analogs as pro-cognitive/anti-dementia agents | author2=Caroline C. Benoist | author3=John W. Wright | author4=Leen H. Kawas | author5=Jyote Bule-Ghogare | author6=Mingyan Zhu | author7=Suzanne M. Appleyard | author8=Gary A. Wayman | author9=Joseph W. Harding | journal=The Journal of Pharmacology and Experimental Therapeutics | date=January 2013 | doi=10.1124/jpet.112.199497 | pmc=3533412 | volume=344 | issue=1 | pages=141–154 | pmid=23055539}}</ref><ref>{{cite journal | title=The Procognitive and Synaptogenic Effects of Angiotensin IV–Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System | date=November 2014 | journal=The Journal of Pharmacology And Experimental Thereapeutics | vauthors=Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW | volume=351 | issue=2 | pages=390–402 | doi=10.1124/jpet.114.218735 | pmid=25187433 | PMC=4201273}}</ref><ref>{{cite journal | title=Facilitation of Hippocampal Synaptogenesis and Spatial Memory by C-Terminal Truncated Nle1-Angiotensin IV Analogs |author1=Caroline C. Benoist |author2=John W. Wright |author3=Mingyan Zhu |author4=Suzanne M. Appleyard |author5=Gary A. Wayman |author6=Joseph W. Harding | journal=The Journal of Pharmacology and Experimental Therapeutics | date=October 2011 | volume=339 | issue=1 | pages=35–44 | doi=10.1124/jpet.111.182220 | pmid=21719467 | pmc=3186286}}</ref><ref>{{cite journal | author1=Phillip M. Uribe | title=Hepatocyte growth factor mimetic protects lateral line hair cells from aminoglycoside exposure | date=January 2015 | author2=Leen H. Kawas | author3=Joseph W. Harding | author4=Allison B. Coffin | journal=Frontiers in Cellular Neuroscience | doi=10.3389/fncel.2015.00003 | pmc=4309183 | volume=9 | issue=3 | pmid=25674052}}</ref><ref>{{cite journal | url=http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142814 | title=The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer's Disease |author1=John W. Wright |author2=Joseph W. Harding | journal=Journal of Alzheimer's Disease | date=January 2015 | volume=45 | issue=4 | pages=985–1000 | doi=10.3233/JAD-142814 | pmid=25649658}}</ref><ref>{{cite journal | title=Small-Molecule-Driven Hepatocyte Differentiation of Human Pluripotent Stem Cells |author1=Richard Siller |author2=Sebastian Greenhough |author3=Elena Naumovska |author4=Gareth J. Sullivan | journal=Stem Cell Reports | date=May 2015 | volume=4 | issue=5 | pages=939–952 | doi=10.1016/j.stemcr.2015.04.001 | pmid=25937370 | pmc=4437467}}</ref><ref>{{cite web | url=http://komonews.com/sponsored/wsu125/32-the-innovators-designing-medicines-holy-grail | title=32. The Innovators: Designing Medicine's Holy Grail | publisher=KOMO News | date=27 August 2015 | accessdate=11 October 2015}}</ref><ref>{{cite web | url=http://www.genengnews.com/gen-news-highlights/brain-connections-in-alzheimer-s-rebuilt-with-new-peptide/81247461/ | title=Brain Connections in Alzheimer's Rebuilt with New Peptide | publisher=GEN News Highlights | date=11 October 2015 | accessdate=11 October 2015}}</ref><ref>{{cite web | url=http://motherboard.vice.com/read/brain-enhancing-smart-drugs-are-going-commercial | title=Brain-Enhancing 'Smart Drugs' Are Going Commercial | publisher=VICE | date=17 July 2014 | accessdate=11 October 2015}}</ref> In an assay of [[neurotrophin|neurotrophic]] activity, Dihexa was found to be seven orders of magnitude more potent than [[brain-derived neurotrophic factor]].<ref>{{cite web | url=https://www.sciencedaily.com/releases/2012/10/121011090653.htm | title=Prospective Alzheimer's drug builds new brain cell connections, improves cognitive function of rats | publisher=ScienceDaily | date=11 October 2012 | accessdate=11 October 2015}}</ref>

According to a patent, "Short duration safety studies with Dihexa have uncovered no apparent [[toxicity]]. Of particular note is a lack of [[neoplasm|neoplastic induction]], since c-Met is recognized as an [[oncogene]]. This is unsurprising since [[oncogenesis]] requires multiple [[mutation]]s including both oncogene induction and [[tumor suppressor gene|tumor suppressor]] attenuation."<ref name="US20150337024">{{US patent reference | number = 0337024 | y = 2015 | m = 11 | d = 26 | inventor = Allison Coffin, Joseph Harding, Leen Kawas, Phillip Uribe | title = Novel Lead Compound for Otoprotection: Targeting HGF Signaling with Dihexa | url = http://www.freepatentsonline.com/y2015/0337024.html}}</ref>

==References==
{{Reflist|2}}

{{Anti-dementia drugs}}
{{Nootropics}}
{{Growth factor receptor modulators}}

[[Category:Antidementia agents]]
[[Category:Designer drugs]]
[[Category:Nootropics]]
[[Category:Peptides]]


{{nervous-system-drug-stub}}